Aclaris Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Aclaris Therapeutics şirketinin toplam hissedar öz sermayesi $130.2M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $182.4M ve $52.2M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$127.72m
Eşitlik	US$130.15m
Toplam yükümlülükler	US$52.24m
Toplam varlıklar	US$182.39m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 0H8T 'nin kısa vadeli varlıkları ( $132.3M ) kısa vadeli yükümlülüklerini ( $18.8M ) aşıyor.

Uzun Vadeli Yükümlülükler: 0H8T şirketinin kısa vadeli varlıkları ( $132.3M ) uzun vadeli yükümlülüklerini ( $33.4M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 0H8T borçsuzdur.

Borcun Azaltılması: 0H8T şirketinin 5 yıl önce borç/öz sermaye oranı 35.1% iken borcu yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: 0H8T şirketinin mevcut serbest nakit akışına göre 3 yıldan fazla bir süre için yeterli nakit pistine sahip olduğu belirtiliyor.

Tahmini Nakit Akışı: 0H8T serbest nakit akışı her yıl % { 8.7 2.4 |round(1)}} yıl boyunca yeterli nakit akışına sahip olacaktır.

Aclaris Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Aclaris Therapeutics, Inc. announced that it expects to receive funding from a group of investors

New major risk - Revenue and earnings growth

Second quarter 2024 earnings released: US$0.15 loss per share (vs US$0.42 loss in 2Q 2023)

Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) dropped from Russell 3000 Growth Index

First quarter 2024 earnings released: US$0.24 loss per share (vs US$0.42 loss in 1Q 2023)

New major risk - Revenue and earnings growth

Aclaris Therapeutics, Inc. to Report Q1, 2024 Results on May 07, 2024

Aclaris Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Aclaris Therapeutics, Inc. Announces Intangible Asset Impairment for the Three Months Ended December 31, 2023

Aclaris Therapeutics, Inc. Announces Intangible Asset Impairment for the Three Months Ended December 31, 2023

Full year 2023 earnings released: US$1.27 loss per share (vs US$1.33 loss in FY 2022)

Aclaris Therapeutics, Inc. Announces Termination of Employment of Gail Cawkwell as Chief Medical Officer

Insufficient new directors

Aclaris Therapeutics, Inc. Announces Douglas Manion Steps Down as President and Member of the Board of Directors

Aclaris Therapeutics, Inc. Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis

Aclaris Therapeutics, Inc. Announces Top-Line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update

New minor risk - Market cap size

Third quarter 2023 earnings released: US$0.41 loss per share (vs US$0.30 loss in 3Q 2022)

Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202)

Chief Financial Officer recently bought US$75k worth of stock

Chief Business Officer recently bought US$100k worth of stock

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: US$0.42 loss per share (vs US$0.31 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.42 loss per share (vs US$0.31 loss in 1Q 2022)

Co-Founder & Chairman recently sold US$510k worth of stock

Full year 2022 earnings released: US$1.33 loss per share (vs US$1.60 loss in FY 2021)

Chief Business Officer recently sold US$59k worth of stock

Aclaris Therapeutics, Inc. Announces Chief Financial Officer Changes

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Second quarter 2022 earnings released: US$0.31 loss per share (vs US$0.34 loss in 2Q 2021)

Insufficient new directors

Aclaris Therapeutics, Inc. Announces Executive Changes

Aclaris Therapeutics, Inc. Appoints Gail Cawkwell as Chief Medical Officer

Aclaris Therapeutics, Inc. Appoints Ian Anderson as Executive Vice President, Translational Research & Development

First quarter 2022 earnings released: US$0.31 loss per share (vs US$0.57 loss in 1Q 2021)

Aclaris Therapeutics, Inc., Annual General Meeting, Jun 02, 2022

Co-Founder recently sold US$896k worth of stock

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Aclaris Therapeutics, Inc. Names James Loerop as Chief Business Officer, Effective January 31, 2022

Aclaris Therapeutics Provides R&D Update

Aclaris Therapeutics Announces Publication of Preclinical Research of Zunsemetinib in Pancreatic Cancer in Science Translational Medicine

Third quarter 2021 earnings released: US$0.34 loss per share (vs US$0.25 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.34 loss per share (vs US$0.28 loss in 2Q 2020)

Director Vincent Milano has joined 3rd company board

Director Vincent Milano has joined 3rd company board

Director Vincent Milano has joined 3rd company board

Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) dropped from Russell Microcap Value Index

Aclaris Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $125.000009 million.

Aclaris Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $125.000009 million.

Aclaris Therapeutics, Inc. Announces Positive Preliminary Topline Data from Phase 2A Trial of ATI-1777

Co-Founder recently sold US$258k worth of stock

First quarter 2021 earnings released: US$0.57 loss per share (vs US$0.37 loss in 1Q 2020)

Aclaris Therapeutics Completes Enrollment in its Phase 2a Clinical Trial of ATI-1777 for Moderate to Severe Atopic Dermatitis

Full year 2020 earnings released: US$1.20 loss per share (vs US$2.75 loss in FY 2019)

Revenue beats expectations

Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) dropped from Russell 2000 Dynamic Index

Aclaris Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $95.964995 million.

Aclaris Therapeutics, Inc. Announces Positive Preliminary Topline Data from 12-Week Phase 2A Trial of Oral ATI-450 for Moderate to Severe Rheumatoid Arthritis

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin